|
HanmiPharm is a South Korean pharmaceutical company that develops, manufactures, and sells prescription drugs, active pharmaceutical ingredients (APIs), and biopharmaceuticals. The company operates through three main business segments: pharmaceuticals, APIs, and overseas pharmaceuticals. In the pharmaceuticals segment, it markets improved and complex generic drugs such as Amozaltan for hypertension, Rosujet for dyslipidemia, Esomezol for gastroesophageal reflux disease, and Hanmitams for benign prostatic hyperplasia, while also focusing on the development of new drugs in areas including obesity, metabolic disorders, and oncology. The API segment, operated through its subsidiary Hanmi Precision Chemical, produces cephalosporin antibiotics and other raw materials for global pharmaceutical companies, and provides CDMO services for high-difficulty peptides, PEG, and mRNA raw materials. The overseas pharmaceuticals segment is managed by Beijing Hanmi Pharmaceutical, which sells products in China, including Mamai for pediatric gastrointestinal issues and Yitanjing for cough and phlegm. The company maintains R&D partnerships and has licensed out technologies to global partners, including Aptose Biosciences. HanmiPharm serves domestic and international markets, with a significant presence in South Korea and China, and exports APIs to numerous countries worldwide. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage hanmi.co.kr |
| Sector Healthcare | IR page hanmi.co.kr/about/investor-relations/ir/event/list.hm | |
|
Tags
prescription drugs, active pharmaceutical ingredients, biopharmaceuticals, cdmo, obesity, metabolic disorders, oncology, antibiotics, peptides, mrna, Amozaltan, Rosujet, Esomezol, Hanmitams, Palfal, Mamai, Yitanjing, Meichang'an, Meiyaping, Hanmi Precision Chemical, Beijing Hanmi Pharmaceutical, Aptose Biosciences, BH3120, HM97662, Epe, Muzonalmac, Maxibufen, Tenten, Siliman
|
Press page hanmi.co.kr/about/news-media/press |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 6.46T |
| Market cap (USD) | $ 4.754B |
| P/E | 29.47 |
| PEG | 1.09 |
| P/BV | 4.60 |
| P/S | 3.90 |
| P/OCF | 23.67 |
| P/FCF | 29.86 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 14.5% |
| ROI | 13.6% |
| ROIC | 18.1% |
| Profit margin | 11.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 27.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 35.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.548T | 1.496T | 1.491T | 1.332T | 1.203T | 1.076T | 1.114T | 1.016T | 916.586B | 882.725B | 1.318T | 761.28B | 730.134B |
| Net profit | 169.554B | 121.315B | 146.231B | 82.792B | 67.025B | 11.959B | 52.11B | 24.891B | 60.434B | 23.326B | 154.443B | 35.51B | 43.933B |
| Free cash flow | 130.048B | 154.226B | 189.186B | 132.949B | 181.974B | 109.719B | -153.685B | -156.286B | -309.959B | 212.708B | -19.353B | -101.999B | 59.423B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 272B | 250B | 183B | 191B | 150B | 220B | 180B | 169B | 239B | 339B |
| ↳ YoY growth | -65.4% | -7.8% | -26.7% | +4.1% | -21.4% | +46.6% | -18.2% | -6.1% | +41.2% | +42.0% |
| ↳ 5y CAGR | -3.7% | -8.0% | -28.2% | -4.1% | -6.4% | -1.6% | +4.6% | +17.7% | ||
| Borrowings, current (KRW) | 43.8B | 278B | 215B | 297B | 400B | 400B | 449B | 481B | 0.00 | 0.00 |
| Borrowings, non-current (KRW) | 49.7B | 146B | 217B | 221B | 179B | 181B | 142B | 82B | 85.9B | 91.8B |
| Bonds payable (KRW) | 50B | 60B | 0.00 | 50B | 113B | 100B | 35B | 75B | 0.00 | 0.00 |
| Cash and deposits (KRW) | 130B | 47.3B | 67.3B | 106B | 146B | 209B | 147B | 55B | 192B | 108B |
| Intangible assets (KRW) | 40.1B | 45.7B | 60.7B | 66.2B | 72.9B | 80.2B | 84.6B | 81B | 94.1B | 113B |
| Right-of-use assets (KRW) | — | 0.00 | 0.00 | 8.09B | 13.4B | 12.7B | 30.4B | 27B | 26.9B | 26.1B |
| Net debt (borrowings + leases - cash) (KRW) | -36.9B | 378B | 365B | 412B | 433B | 372B | 445B | 508B | -106B | -16.5B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 413B | -62.9B | 26B | 12.4B | 152B | 202B | 162B | 217B | 193B | 173B |
| Purchases of property, plant and equipment (KRW) | -200B | -247B | -182B | -166B | -41.8B | -19.9B | -29.3B | -27.4B | -39.3B | -43B |
| Purchases of intangible assets (KRW) | -23.8B | -15.3B | -29B | -12.2B | -16B | -14.5B | -20.3B | -16.4B | -23.3B | -33.5B |
| Change in receivables (cash effect) (KRW) | 527B | -16.3B | 58.6B | -10.1B | 32.5B | 2.3B | 904M | 703M | -61.1B | -87.3B |
| Change in inventories (cash effect) (KRW) | -34.7B | -42.7B | -27.1B | -74.1B | 4.88B | 18.9B | -14.4B | -16.9B | 1.93B | -37B |
| Change in payables (cash effect) (KRW) | -7.53B | -3.3B | 3.34B | -7.14B | -5.31B | 9.79B | -2.74B | 5.57B | -24.4B | 256M |
| Dividends paid (cash effect) (KRW) | -20.4B | 0.00 | -8.96B | -5.66B | -8.14B | -5.88B | -5.99B | -18B | -12.6B | -30.9B |
| Share buybacks (cash effect) (KRW) | -7.13B | -6.45B | -5.59B | -3.87B | -3.08B | -4.87B | -3.83B | -3.07B | -3.28B | 0.00 |
| Interest paid (cash effect) (KRW) | -11.8B | -13.3B | -18.9B | -23.3B | -23.6B | -18.3B | -19.5B | -27.8B | -24.7B | -17.1B |
| Income taxes paid (cash effect) (KRW) | -11.8B | -11B | -13.7B | -8.03B | -14.7B | -6.6B | -29.6B | -31.4B | -22.1B | -46.3B |
| Operating cash flow before change in receivables (KRW) | -115B | -46.6B | -32.6B | 22.5B | 119B | 200B | 161B | 216B | 255B | 260B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 189B | -325B | -185B | -166B | 93.7B | 167B | 113B | 173B | 131B | 96.5B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 17.3B | 64.4B | 27.9B | 42.6B | 20.7B | 107B | 94.8B | 111B | 175B | 194B |
| Comprehensive income to owners (KRW) | 12.1B | 58.7B | 19.2B | 30.1B | 15B | 83.7B | 78.8B | 92.8B | 142B | 173B |
| Provision for credit losses (KRW) | -2.25B | 797M | 2.15B | 2.1B | 374M | 5.12B | 723M | 1.28B | -594M | 3.35B |
| Credit cost ratio (credit losses / average receivables) (%) | 0.4% | 0.3% | 1.0% | 1.1% | 0.2% | 2.8% | 0.4% | 0.7% | 0.3% | 1.2% |
| Reported | Apr 2, 2018 | Mar 30, 2020 | Mar 30, 2020 | Mar 30, 2020 | Mar 18, 2021 | Mar 19, 2024 | Mar 19, 2024 | Mar 19, 2024 | Mar 18, 2025 | Mar 20, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding HanmiPharm
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| OZEM | 6.90% | 11,503 | $ 3.855M | Nov 17, 2026 |
| AVEE | 0.23% | 936 | $ 307.273K | Nov 16, 2026 |
| DEHP | 0.06% | 638 | $ 226.821K | Nov 12, 2026 |
| DEXC | 0.04% | 300 | $ 106.656K | Nov 12, 2026 |
| DFSE | 0.04% | 623 | $ 221.488K | Nov 12, 2026 |
| DFEM | 0.03% | 6,431 | $ 2.286M | Nov 12, 2026 |
| DFAE | 0.02% | 4,619 | $ 1.642M | Nov 12, 2026 |
| DFAX | 0.01% | 4,146 | $ 1.474M | Nov 12, 2026 |
| AVEM | 0.01% | 5,573 | $ 1.83M | Nov 16, 2026 |
| AVXC | 0.01% | 171 | $ 56.136K | Nov 16, 2026 |